杨震宇, 於江泉. 宏基因组二代测序诊断免疫缺陷患者感染性疾病的研究进展[J]. 实用临床医药杂志, 2024, 28(9): 129-133. DOI: 10.7619/jcmp.20240557
引用本文: 杨震宇, 於江泉. 宏基因组二代测序诊断免疫缺陷患者感染性疾病的研究进展[J]. 实用临床医药杂志, 2024, 28(9): 129-133. DOI: 10.7619/jcmp.20240557
YANG Zhenyu, YU Jiangquan. Research progress of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics[J]. Journal of Clinical Medicine in Practice, 2024, 28(9): 129-133. DOI: 10.7619/jcmp.20240557
Citation: YANG Zhenyu, YU Jiangquan. Research progress of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics[J]. Journal of Clinical Medicine in Practice, 2024, 28(9): 129-133. DOI: 10.7619/jcmp.20240557

宏基因组二代测序诊断免疫缺陷患者感染性疾病的研究进展

Research progress of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics

  • 摘要: 宏基因组二代测序(mNGS)通过识别临床样本中的微生物核酸来协助诊断, 是用于免疫功能低下患者感染性疾病诊断的有效工具。mNGS能够在常规检测为阴性的患者中识别出致病生物体, 但目前在免疫力低下患者中, 评估mNGS诊断感染效能的报告仅限于个体患者或小型回顾性研究。本文回顾分析文献, 为在临床中开展mNGS相关研究提供新思路。

     

    Abstract: Metagenomic next generation sequencing (mNGS) based diagnostics that identify microbial nucleic acids in clinical samples may be a useful tool in addressing some of these challenges. Studies of mNGS in immunocompromised hosts have demonstrated that these diagnostics are capable of identifying causative organisms in a subset of patients for whom conventional testing has been negative. But the reports evaluating the diagnostic efficiency of mNGS in immunocompromised patients are limited to individual patients or small retrospective studies at present. This article reviewed and analyzed the literature to provide new ideas for conducting related research on mNGS in clinical practice.

     

/

返回文章
返回